Induction of clinical remission (CDAI < or = 150) · patients with Induction of remission or response in Crohn's disease
Mesalamine (4 ‐ 4.5 g/day) may leads to lower induction of remission (CDAI < or = 150) ‐ Pentasa (4 g/day) compared with budesonide (low certainty).
2 findings from 1 review
Clinical remission or improvement · patients with Induction of remission or response in Crohn's disease
It is very uncertain whether mesalamine changes induction of remission (CDAI < 150) or clinical improvement ‐… compared with sulfasalazine (alone or (very low certainty).
2 findings from 1 review
Remission · patients with Induction of remission or response in Crohn's disease
Sulfasalazine showed no clear difference in induction of remission (CDAI <150) (Random Effects Model) compared with placebo (moderate certainty).
1 finding from 1 review
CDAI <150 at 24 weeks · patients with Induction of remission or response in Crohn's disease
Sulfasalazine probably leads to lower induction of remission (CDAI <150) compared with corticosteroids (moderate certainty).
1 finding from 1 review
Remission · patients with Induction of remission or response in Crohn's disease
Sulfasalazine probably leads to lower induction of remission compared with sulfasalazine and corticosteroids (moderate certainty).
1 finding from 1 review
Decrease in CDAI >=50, HBI >=2 or improvement/remission (as defined by Tvede et al) · patients with Induction of remission or response in Crohn's disease
Controlled‐release mesalamine (1 ‐ 2 g/day) showed no clear difference in decrease in CDAI >=50, HBI >=2 or improvement/remission (as defined… compared with placebo (low certainty).
1 finding from 1 review
Induction of remission (CDAI <=150 + decrease of >=50 or as defined by Tvede et al) · patients with Induction of remission or response in Crohn's disease
Controlled‐release mesalamine (1 ‐ 2 g/day) showed no clear difference in induction of remission (CDAI <=150 + decrease of >=50 or as defined… compared with placebo (low certainty).
1 finding from 1 review
Mean change in baseline CDAI (Random effects model) · patients with Induction of remission or response in Crohn's disease
1 finding from 1 review
Mean change in baseline CDAI (Fixed effects model) · patients with Induction of remission or response in Crohn's disease
1 finding from 1 review
Pain‐free at 2 hours · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
High
Pain‐free at 1 hour · adults with episodic tension‐type headache
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Use of rescue medication · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Pain‐free or mild pain at 2 hours · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Any adverse event · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Serious adverse events · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Pain‐free at 1 hour · adults with episodic tension‐type headache
2 findings from 1 review
no estimate extracted
Studies not reported
Moderate
no estimate extracted
Studies not reported
Moderate
Use of rescue medication · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Pain‐free or mild pain at 2 hours · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
High
Any adverse event · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
High
Serious adverse events · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate